This database contains 125 studies, archived under the term: "Alzheimer"
Click here to filter this large number of results.
Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer’s patients–an open-label trial
Kennelly, Sean,
Abdullah, Laila,
Kenny, Rose Anne,
Mathura, Venkat,
Luis, Cheryl A.,
Mouzon, Benoit,
Crawford, Fiona,
Mullan, Michael,
Lawlor, Brian
Background: Evidence suggests that dihydropyridine calcium channel blockers may be useful in preventing and treating Alzheimer’s disease (AD).; Objective: In an open-label trial of safety and tolerability of nilvadipine in patients with AD, we examined cognition and executive function over a short time period to determine an influence of nilvadipine on these outcomes.; Method: We […]
Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine
Iwasaki, Koh,
Kosaka, Kenji,
Mori, Hideo,
Okitsu, Reina,
Furukawa, Katsutoshi,
Manabe, Yuta,
Yoshita, Mitsuhiro,
Kanamori, Aya,
Ito, Nobuo,
Wada, Kenji,
Kitayama, Michio,
Horiguchi, Jun,
Yamaguchi, Shuhei,
Takayama, Shin,
Fukuhara, Ryuji,
Ouma, Shinji,
Nakano, Seigo,
Hashimoto, Mamoru,
Kinoshita, Toru
Background: This multicentre open-label trial examined the efficacy and safety of the traditional Japanese medicine, or Kampo medicine, yokukansan (YKS), for behavioural and psychological symptoms of dementia (BPSD) in patients with dementia with Lewy bodies.; Methods: Sixty-three dementia with Lewy bodies patients with probable BPSD (M:W, 30:33; mean age, 78.2±5.8 years) were enrolled and treated […]
Two galantamine titration regimens in patients switched from donepezil
Engedal, K.,
Davis, B.,
Richarz, U.,
Han, J.,
Schäuble, B.,
Andreasen, N.
Objectives: In addition to inhibiting acetylcholinesterase, galantamine has allosteric-modulating activity at nicotinic receptors. This may make galantamine an attractive option for patients starting treatment for Alzheimer’s disease (AD), but also for those who have not benefited from their current therapy. This study explored outcomes in subjects with AD transitioning from donepezil because of insufficient tolerability […]
Medication adherence and tolerability of Alzheimer’s disease medications: study protocol for a randomized controlled trial
Campbell, Noll L.,
Dexter, Paul,
Perkins, Anthony J.,
Gao, Sujuan,
Li, Lang,
Skaar, Todd C.,
Frame, Amie,
Hendrie, Hugh C.,
Callahan, Chris M.,
Boustani, Malaz A.
Background: The class of acetylcholinesterase inhibitors (ChEI), including donepezil, rivastigmine, and galantamine, have similar efficacy profiles in patients with mild to moderate Alzheimer’s disease (AD). However, few studies have evaluated adherence to these agents. We sought to prospectively capture the rates and reasons for nonadherence to ChEI and determine factors influencing tolerability and adherence.; Methods/design: […]
Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer’s disease
Weiner, Michael W.,
Sadowsky, Carl,
Saxton, Judith,
Hofbauer, Robert K.,
Graham, Stephen M.,
Yu, Sung Yun,
Li, Shaoyi,
Hsu, Hai-An,
Suhy, Joyce,
Fridman, Moshe,
Perhach, James L.
Background: This study was designed to assess changes in brain volume and cognitive abilities in memantine-treated patients with Alzheimer’s disease (AD) by using an exploratory, single-arm, delayed-start design.; Methods: Cholinesterase inhibitor-treated patients with AD (N = 47; Mini-Mental State Examination score range: 15-23) were enrolled in an observational lead-in period (weeks: 1-24), followed by an […]
Memantine and functional communication in Alzheimer’s disease: results of a 12-week, international, randomized clinical trial
Saxton, Judith,
Hofbauer, Robert K.,
Woodward, Michael,
Gilchrist, Nigel L.,
Potocnik, Felix,
Hsu, Hai-An,
Miller, Michael L.,
Pejović, Vojislav,
Graham, Stephen M.,
Perhach, James L.
Post hoc analyses suggest that memantine treatment may provide communication-related benefits in patients with Alzheimer’s disease (AD). In this 12-week, international, randomized, double-blind, placebo-controlled trial of memantine (10 mg bid), the functional communication abilities of patients with AD (MMSE range: 10-19) were assessed using the Functional Linguistic Communication Inventory (FLCI; primary measure). Two combined subscales […]
Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients
Han, Hyun Jeong,
Kim, Byeong C.,
Lee, Jun-Young,
Ryu, Seung-Ho,
Na, Hae-Ri,
Yoon, Soo Jin,
Park, Hyun Young,
Shin, Joon Hyun,
Cho, Soo-Jin,
Yi, Hyon Ah,
Choi, Mun Seong,
Heo, Jae-Hyeok,
Park, Kyung Won,
Kim, Kwang K.,
Choi, Seong Hye
Background/aims: The apolipoprotein E (APOE) genotype in response to pharmacological treatments in patients with Alzheimer’s disease (AD) remains a matter of controversy. This analysis investigated the effect of the APOE genotype on the clinical response to rivastigmine transdermal patch monotherapy or memantine plus rivastigmine patch in patients with mild to moderate AD.; Methods: Two hundred […]